The #1 employee-ranked health benefit1*

Only ~30% of diagnosed cancers have recommended screening available.2 The Galleri® multi-cancer early detection test can help fill that critical gap in your company’s cancer strategy by detecting a signal shared by more than 50 types of cancer, all with a simple blood draw.

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.

*Market research included 1,000 respondents, age 40+, who are employed full-time at larger organizations.

Black woman with short hair wearing a white polka dot shirt with a gray jacket sitting at a table smiling at an out of focus woman in a blue and black shirt

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.

*Market research included 1,000 respondents, age 40+, who are employed full-time at larger organizations.

Why Galleri?

Our company’s mission, to detect cancer early, when it can be cured, aligns with your goal to improve employee health. And detecting cancer early, when it may also be more cost-effective to treat,3 is also critical in addressing your #1 driver of medical spend.4

purple text indicating 26%

Based on modeled data, the Galleri test has the potential to shift cancer detection to earlier stages, showing a 26% reduction in 5-year cancer-related mortality5

blue text indicating 98%

Claims data analysis shows that the Galleri test can potentially detect 98% of employees’ diagnosed cancer types6

purple text indicating 3x

Early-stage cancer was an average of 3X less expensive to treat vs late-stage in the first year after diagnosis3

Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer.

How Galleri Works

All cells, healthy and cancerous, release DNA into the bloodstream. But DNA from cancer cells is different from DNA from healthy cells. Using next-generation DNA sequencing, machine learning, and AI, the Galleri test can detect a cancer signal in the blood and predict the tissue or organ where the cancer signal originated.

illustrated graphic video explaining how the Galleri test works

Cancer and Health Equity

Research shows that cancer screening rates are substantially lower among those from racial/ethnic minorities compared to their white counterparts.7 The Galleri test offers equitable access to multi-cancer screening with just 1 blood draw, which can be completed almost anywhere: workplace events, home visits, and 6,600+ partner labs nationwide.

Galleri should be used in addition to healthcare provider recommended screening tests.

Bald Black man wearing a button up denim shirt sitting at a table with his hands folded in front of him

The Galleri Experience

We partner with you to leverage customizable emails, direct mailers, flyers/posters, presentations, landing page and more to drive employee awareness and education about the Galleri test.

Employees can request their test through the Galleri portal. Once ordered by a physician, the test kit ships directly to the employee with information on how to schedule a blood draw at a nearby partner clinic, at an onsite event, or in their own home.

Results are returned about 2 weeks after GRAIL receives the sample in our lab, and all “Cancer Signal Detected” results are shared live with the employee by a healthcare professional.

All employees who receive a “Cancer Signal Detected” result are contacted by the GRAIL Patient Advocate who, if necessary, assists with finding an in-network primary care provider (PCP) to complete diagnostic next steps and connect the employee with other relevant benefits. GRAIL also provides access to expert peer-to-peer support for the employee’s PCP.

Get Started

Fill out this form and we’ll reach out to discuss how the Galleri test could positively impact your employees and organization

  1. What describes you best?

  2. What are you looking for?

  3. Fill in the form

Frequently Asked Questions

The Galleri test looks for signals present in the blood that may be associated with cancer at the time of your blood draw. If a cancer signal is detected, Galleri results include a prediction of the organ or tissue type associated with the cancer signal to help your healthcare provider guide next steps.

The Galleri test should be used in addition to guideline-recommended cancer screening, such as mammography, colonoscopy, prostate specific antigen (PSA) or cervical cancer screening. Galleri is recommended for use in adults with an elevated risk of cancer, such as those aged 50 or older.

Once an employee's test has been ordered by a healthcare provider, they will have access to an online blood draw finder with GRAIL's 6,600+ lab partner locations, from which they can select their desired appointment location, date and time. If they prefer, the employee can also call GRAIL customer service to schedule an in-home blood draw. The employee will need a copy of their completed test requisition form and an unopened Galleri specimen collection kit for the blood draw.

The Galleri test detects a cancer signal shared by more than 50 cancers. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. Recommended routine cancer screening tests such as colonoscopy or mammograms are commonly used and have been shown to reduce cancer deaths. The Galleri test is intended to be used in addition to and not replace these tests and is expected to increase the benefits of early cancer detection. Missing recommended screening or ignoring symptoms could lead to a delayed diagnosis of cancer. Ask your healthcare provider about what cancer screening tests are right for you.

All employees who receive a Cancer Signal Detected result on their Galleri test receive a phone call from a trained healthcare provider to explain the results and ensure the employee has a primary care physician (PCP) with whom the results can be shared. A GRAIL patient advocate can connect the employee's PCP with expert peer-to-peer consultation services regarding next steps for diagnostic testing. If the employee does not currently have a PCP, the patient advocate will provide them with local, in-network primary care navigation support. Once a PCP is found, the patient advocate can provide connections to expert peer-to-peer physician support and conducts ongoing follow-up with the employee to confirm the appropriate next steps are taken towards diagnostic evaluation.

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of ​“No Cancer Signal Detected” does not rule out cancer. A test result of ​“Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

  1. Market research data on file GA-2022-0089.

  2. Incident cancers with USPSTF recommended screening. SEER Stat Database: Incidence - SEER 18 Regs Research Data, Nov 2017 Sub. Includes persons aged 50+ diagnosed 2006-2015.

  3. Reddy SR, et al. Cost of cancer management by stage at diagnosis among Medicare beneficiaries. Curr Med Res Opin. 2022;38(8):1285-1294. DOI: doi.org/10.1080/03007995.2022.2047536.

  4. Business Group on Health. 2023 Large Employers’ Health Care Strategy and Plan Design Survey. August 2022. Available at: https://www.businessgrouphealth.org/resources/2023-large-employers-health-care-strategy-survey-intro.

  5. Hubbell E, et al. Modeled reductions in late-stage cancer with a multi-cancer early detection test. Cancer Epidemiol Biomarkers Prev. 2021;30(3):460-468. DOI: doi.org/10.1158/1055-9965.EPI-20-1134

  6. Analysis of MarketScan claims database completed by GRAIL, LLC, July 2022. Data on file GA-2022-0085.

  7. https://cancerprogressreport.aacr.org/disparities/cdpr22-contents/cdpr22-disparities-in-cancer-screening-for-early-detection/.